drugset
Drugs / Meningococcal C oligosaccharide conjugated vaccine
last change Mar 2017 re-read 3 minutes ago

Meningococcal C oligosaccharide conjugated vaccine

also known as MenC-CRM

Vaccine

Developed for
meningococcal meningitis
Investigated by
Novartis Vaccines

Trials 1

today NCT01339923 · Ph 3
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01339923 Apr 2011 → Jan 2014 meningococcal meningitis Novartis Vaccines Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Meningococcal C oligosaccharide conjugated vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01339923 ↗
Known as MenC-CRM “This study (NCT01339923) investigated the immunogenicity and safety of MenC CRM-conjugated vaccine (MenC-CRM) concomitantly administered with MenB vaccine (4CMenB).” PMID 28318767 ↗ Mar 2017
Modality Vaccine “MenC CRM-conjugated vaccine (MenC-CRM)” PMID 28318767 ↗ Mar 2017